Combination therapy for malignant glioma based on PTEN status (Q37316986)

19 August 2017

1 reference

title

Combination therapy for malignant glioma based on PTEN status (English)

1 reference

19 August 2017

Javier Gonzalez

1

1 reference

PubMed ID

18983237

19 August 2017

John de Groot

series ordinal

2

1 reference

19 August 2017

1 November 2008

1 reference

Expert Review of Anticancer Therapy

19 August 2017

1 reference

19 August 2017

8

1 reference

19 August 2017

11

1 reference

19 August 2017

1767-1779

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Molecular changes in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Molecular pathology of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

PTEN mutations in gliomas and glioneuronal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

PTEN methylation and expression in glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

PIK3CA alterations in primary (de novo) and secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Amplified cellular oncogenes in neoplasms of the human central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Biomarkers to predict response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Malignant glioma: genetics and biology of a grave matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Coordinate regulation of translation by the PI 3-kinase and mTOR pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Strategies for optimizing combinations of molecularly targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Combining radiation and molecular targeting in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Predicting outcome and tailoring treatment in high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1767

10.1586/14737140.8.11.1767

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18983237